VANCOUVER, BC / ACCESSWIRE / October 17, 2018 / Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSXV:VIR) (OTC:VIRFF) is pleased to announce that its wholly owned subsidiary, Experion Biotechnologies Inc. ("Experion"), has received an amended license from Health Canada allowing for the sale of dried flower directly to customers holding a valid medical prescription. This amended license permits Experion to register medical patients as customers, process purchase orders, and ship to patients directly.

Approval of direct sale to patients now completes and rounds out the portfolio of sales license amendments held by Experion for the Canadian medical market. Experion may now sell starter material and dried flower to both wholesale and end customers nationally across Canada. By achieving the final sales license, the company will transition to several new licenses under the Cannabis Act with the same capabilities taking effect on October 17, 2018.Experion anticipates launching its e-marketplace for medical patients in December 2018 through its website, www.expbiotech.com.

Mr. Jay Garnett, Chief Executive Officer of Viridium, commented, "With approval for sale to medical patients, Experion is now open for business to every kind of medical cannabis buyer in Canada. We’re very proud of our team in Mission who have gone above and beyond in this last licensing push. This amendment represents the culmination of all of our work over the past 14 months since receiving our LP."

About Viridium

More information about Viridium can be found under the Company's profile on SEDAR at www.sedar.com.

For further information:

Viridium Pacific Group Ltd.
Jarrett Malnarich
Tel: (604) 837-8688
[email protected]
www.viridiumpacific.com

Renmark Financial Communications Inc.
Melanie Barbeau: [email protected]
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

SOURCE: Viridium Pacific Group Ltd.